Sphingosine 1-phosphate receptor modulators in multiple sclerosis.

Abstract

Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease-modifying therapy for multiple sclerosis (MS). Subtype 1 S1P receptors are expressed on the surfaces of lymphocytes and are important in regulating egression from lymph nodes. The S1P receptor modulators indirectly antagonize the receptor's function and sequester lymphocytes in lymph nodes. Fingolimod was the first S1P agent approved in the USA in 2010 for relapsing MS after two phase III trials (FREEDOMS and TRANSFORMS) demonstrated potent efficacy, and good safety and tolerability. Post-marketing experience, as well as a third phase III trial (FREEDOMS II), also showed favorable results. More selective S1P receptor agents-ponesimod (ACT128800), siponimod (BAF312), ozanimod (RPC1063), ceralifimod (ONO-4641), GSK2018682, and MT-1303-are still in relatively early stages of development, but phase I and II trials showed promising efficacy and safety. However, these observations have yet to be reproduced in phase III clinical trials.

• Authors: Adnan M Subei, Jeffrey A Cohen
• Journal: CNS drugs (CNS Drugs) Vol. 29 Issue 7 Pg. 565-75 (Jul 2015) ISSN: 1179-1934 [Electronic] New Zealand
• PMID: 26239599 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Immunologic Factors
• Receptors, Lysosphingolipid

Topics

• Animals
• Clinical Trials as Topic
• Humans
• Immunologic Factors (administration & dosage, adverse effects, pharmacology)
• Multiple Sclerosis (drug therapy, metabolism)
• Receptors, Lysosphingolipid (metabolism)